In the Digital Genomics Group we are in pursuit of better understanding the mechanisms behind the accumulation of genomic alterations in human tumours, and transforming this knowledge into actionable insights for cancer diagnosis, prognosis, and treatment selection.

We specialise in developing cutting-edge computational methodologies, powered by artificial intelligence (AI), to characterise the molecular processes driving tumour development. By analysing the genomic patterns left by the different processes generating somatic mutations, known as mutational signatures, and integrating them with patient-specific clinical, epidemiological, and germline genetic data, we aim to implement prevention strategies and develop novel clinical biomarkers. Our approach seeks to enhance the current understanding of the mechanisms underlying cancer initiation and progression, ultimately improving patient outcomes.

We are also committed to applying these innovative methods to diverse cohorts of cancer patients. By doing so, we aim to advance our understanding of the dynamics and evolution of tumours in different populations across the world, exploring variations that may inform more precise and equitable approaches to cancer care.